NovoCure Q4 2022 Earnings Report $30.51 +0.66 (+2.21%) (As of 12/3/2024 06:07 PM ET) NovoCure EPS ResultsActual EPS-$0.36Consensus EPS -$0.32Beat/MissMissed by -$0.04One Year Ago EPS-$0.25NovoCure Revenue ResultsActual Revenue$128.43 millionExpected Revenue$127.20 millionBeat/MissBeat by +$1.23 millionYoY Revenue Growth-3.60%NovoCure Announcement DetailsQuarterQ4 2022Date2/23/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseSEC FilingNVCR Earnings HistorySlide DeckFull Screen Slide DeckPowered by Lock in this disruptor’s share price before 12/5 (Ad)Spencer Rascoff co-founded Zillow. Austin Allison sold his company to Zillow for $125M. Now they’ve joined forces to launch a venture transforming the $1.3T vacation home market – and the results are already turning heads. This company is leading the co-ownership revolution, offering buyers a chance to own a fraction of a luxury vacation home instead of the entire thing. It’s a model that’s unlocked new demand and earned them over $100M in gross profits in four years.Don’t miss your chance to maximize your stake in this co-ownership revolution. NovoCure Earnings HeadlinesNovoCure (NASDAQ:NVCR) Raised to Outperform at Evercore ISIDecember 4 at 3:15 AM | americanbankingnews.comNovocure seeks approval after pancreatic cancer wearable scores at Phase IIIDecember 4 at 2:38 AM | msn.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…December 4, 2024 | Timothy Sykes (Ad)NovoCure’s PANOVA-3 Trial Success Boosts Oncology ProspectsDecember 3 at 2:26 AM | markets.businessinsider.comWedbush Reiterates Neutral Rating for NovoCure (NASDAQ:NVCR)December 3 at 1:30 AM | americanbankingnews.comNovocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment SurgesDecember 2 at 3:57 PM | msn.comSee More NovoCure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NovoCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your email. Email Address About NovoCureNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.View NovoCure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
